Allogene Therapeutics

Alison Moore, Ph.D., Chief Technology Officer

Oct. 13 | 4:15pm | AVROBIO Ballroom

San Francisco, CA
(NASDAQ: ALLO)

In-person Presentation
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
www.allogene.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions